FDA denies GSK's epilepsy drug

09/23/2007 | Bloomberg1

The drug regulator has declined to approve the extended-release formulation of GlaxoSmithKline's epilepsy pill Lamictal, claiming that further analyses of previously submitted data are needed for its approval, a company spokeswoman said. The company says it anticipates generic competition for the drug by January 2009.

View Full Article in:

Bloomberg1

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Manager, Business Conduct
Gilead
Foster City, CA
Product Patent Attorney
Gilead
Foster City, CA
Employment Counsel
Gilead
Foster City, CA
Junior to Mid-Level FDA Associate
Morgan Lewis
Washington, DC
Global Counsel - Advertising and Promotions
Mylan Inc.
Washington, DC